A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing that blocking two proteins can halt and even reverse lung scarring in pre-clinical models.
To continue reading click here
Virginia Tech team identifies proteins that can reverse lung scarring
